Matches in SemOpenAlex for { <https://semopenalex.org/work/W1930543669> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W1930543669 endingPage "175" @default.
- W1930543669 startingPage "166" @default.
- W1930543669 abstract "Abstract Purpose The aim of this study was to quantitatively analyze clinically significant adverse reactions (CSARs) added to drug package inserts after approval and to investigate the time to these post‐approval additions as an indicator of safety‐related regulatory actions. Methods Drugs containing new active ingredients that had been approved in Japan from April 2001 to December 2010 were analyzed. We examined CSARs that had been reported in the first version of the package inserts and subsequent additions through notifications from Japan's Ministry of Health, Labour and Welfare until the end of 2011. Relative risks (RRs) for post‐approval addition of CSARs were calculated for various categories of disorders. The median lengths of time to post‐approval addition of CSARs were compared. Results A total of 238 drugs were examined. Of the 2487 CSARs associated with these drugs, 737 had been added after approval. The analysis revealed a higher likelihood for post‐approval addition of CSARs for “Hepatobiliary disorders” (RR: 1.41; 95% confidence interval [CI]: 1.19–1.68), “Gastrointestinal disorders” (RR: 1.35; 95%CI: 1.10–1.66), and “Musculoskeletal and connective tissue disorders” (RR: 1.52; 95%CI: 1.11–2.07). In contrast, “Cardiac disorders” showed reduced likelihood in comparison with other disorders. For the time until post‐approval addition of CSARs, “Skin and subcutaneous tissue disorders” showed the longest durations, with a median of 3020 days. Conclusions Our quantitative analysis suggests that some CSARs were added more frequently to package inserts after approval and that time to post‐approval additions of CSARs varied with the types of adverse drug reactions. These results can support the coherent implementation of pharmacovigilance activities. Copyright © 2014 John Wiley & Sons, Ltd." @default.
- W1930543669 created "2016-06-24" @default.
- W1930543669 creator A5000020934 @default.
- W1930543669 creator A5015301818 @default.
- W1930543669 creator A5028092128 @default.
- W1930543669 date "2014-04-15" @default.
- W1930543669 modified "2023-10-10" @default.
- W1930543669 title "Post‐approval appending of CSARs to drug package inserts: an analysis of the types of adverse reactions and time to addition" @default.
- W1930543669 cites W188729947 @default.
- W1930543669 cites W1988899296 @default.
- W1930543669 cites W1993288224 @default.
- W1930543669 cites W2022245473 @default.
- W1930543669 cites W2031301975 @default.
- W1930543669 cites W2033663921 @default.
- W1930543669 cites W2079439532 @default.
- W1930543669 cites W2099000615 @default.
- W1930543669 cites W2157584018 @default.
- W1930543669 cites W4247353963 @default.
- W1930543669 cites W4297633045 @default.
- W1930543669 doi "https://doi.org/10.1002/pds.3629" @default.
- W1930543669 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24737526" @default.
- W1930543669 hasPublicationYear "2014" @default.
- W1930543669 type Work @default.
- W1930543669 sameAs 1930543669 @default.
- W1930543669 citedByCount "4" @default.
- W1930543669 countsByYear W19305436692017 @default.
- W1930543669 countsByYear W19305436692018 @default.
- W1930543669 countsByYear W19305436692020 @default.
- W1930543669 countsByYear W19305436692022 @default.
- W1930543669 crossrefType "journal-article" @default.
- W1930543669 hasAuthorship W1930543669A5000020934 @default.
- W1930543669 hasAuthorship W1930543669A5015301818 @default.
- W1930543669 hasAuthorship W1930543669A5028092128 @default.
- W1930543669 hasConcept C126322002 @default.
- W1930543669 hasConcept C138885662 @default.
- W1930543669 hasConcept C197934379 @default.
- W1930543669 hasConcept C27206212 @default.
- W1930543669 hasConcept C2780035454 @default.
- W1930543669 hasConcept C2993432071 @default.
- W1930543669 hasConcept C44249647 @default.
- W1930543669 hasConcept C4892016 @default.
- W1930543669 hasConcept C521751864 @default.
- W1930543669 hasConcept C71924100 @default.
- W1930543669 hasConcept C82789193 @default.
- W1930543669 hasConcept C98274493 @default.
- W1930543669 hasConceptScore W1930543669C126322002 @default.
- W1930543669 hasConceptScore W1930543669C138885662 @default.
- W1930543669 hasConceptScore W1930543669C197934379 @default.
- W1930543669 hasConceptScore W1930543669C27206212 @default.
- W1930543669 hasConceptScore W1930543669C2780035454 @default.
- W1930543669 hasConceptScore W1930543669C2993432071 @default.
- W1930543669 hasConceptScore W1930543669C44249647 @default.
- W1930543669 hasConceptScore W1930543669C4892016 @default.
- W1930543669 hasConceptScore W1930543669C521751864 @default.
- W1930543669 hasConceptScore W1930543669C71924100 @default.
- W1930543669 hasConceptScore W1930543669C82789193 @default.
- W1930543669 hasConceptScore W1930543669C98274493 @default.
- W1930543669 hasIssue "2" @default.
- W1930543669 hasLocation W19305436691 @default.
- W1930543669 hasLocation W19305436692 @default.
- W1930543669 hasOpenAccess W1930543669 @default.
- W1930543669 hasPrimaryLocation W19305436691 @default.
- W1930543669 hasRelatedWork W182432352 @default.
- W1930543669 hasRelatedWork W1972231143 @default.
- W1930543669 hasRelatedWork W2247420465 @default.
- W1930543669 hasRelatedWork W2325796816 @default.
- W1930543669 hasRelatedWork W2330033385 @default.
- W1930543669 hasRelatedWork W2330074134 @default.
- W1930543669 hasRelatedWork W262676183 @default.
- W1930543669 hasRelatedWork W2976934717 @default.
- W1930543669 hasRelatedWork W4205529513 @default.
- W1930543669 hasRelatedWork W2215772794 @default.
- W1930543669 hasVolume "24" @default.
- W1930543669 isParatext "false" @default.
- W1930543669 isRetracted "false" @default.
- W1930543669 magId "1930543669" @default.
- W1930543669 workType "article" @default.